SPCs: protection of active ingredients, new and old
Joel Beevers, Michael Pears and Stephanie Pilkington explore the practical impact of recent CJEU case law in Royalty Pharma and Teva v Gilead on what constitutes ‘protection’ of active ingredients by the basic patent in the context of SPCs; how patent specifications can be optimised for this purpose; and how it can influence patent filing strategies.